Cargando…
An Unusually Prolonged Case of FGF23-mediated Hypophosphatemia Secondary to Ferric Carboxymaltose Use
Ferric carboxymaltose (FCM)-induced hypophosphatemia is seen in up to 75% of patients receiving this therapy for iron deficiency anemia. Hypophosphatemia has been attributed to increased circulating levels of fibroblast growth factor-23 (FGF23), the transcription of which is upregulated in an iron-d...
Autores principales: | Arora, Ipsa, Kaprove, Alison, Perrone, Ronald, Ceglia, Lisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612470/ https://www.ncbi.nlm.nih.gov/pubmed/37908221 http://dx.doi.org/10.1210/jcemcr/luad117 |
Ejemplares similares
-
Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020) -
Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
por: Fang, Wendy, et al.
Publicado: (2019) -
MON-344 Uncommon Etiology of Hypophosphatemia and Secondary Hyperparathyroidism: Ferric Carboxymaltose Infusion
por: Sever, Sakine
Publicado: (2020) -
Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose
por: Schaefer, Benedikt, et al.
Publicado: (2021) -
Severe Hypophosphatemia Following Ferric Carboxymaltose in a Patient With Inflammatory Bowel Disease
por: Ali, Abuobeida, et al.
Publicado: (2021)